Evaluation of the Effect of Lymph Node Status on the Survival of Non-Small Cell Lung Cancer Patients With Brain Metastases: Applications of a Novel Grade Prognostic Assessment Score Model Involving N Stage

Overview

Journal Front Oncol

Specialty Oncology

Date 2020 Nov 16

PMID 33194635

Citations 5

Authors

Jianfei Zhu

Wuping Wang

Shuonan Xu

Chenghui Jia

Qingqing Zhang

Yanmin Xia

Wenchen Wang

Miaomiao Wen

Xuejiao Wang

Hongtao Wang

Zhipei Zhang

Ling Cai

Lanjun Zhang

Tao Jiang

Affiliations

Soon will be listed here.

Abstract

Background: Grade prognostic assessment (GPA) is widely used to evaluate the prognosis of non-small cell lung cancer (NSCLC) patients with brain metastases (BMs). This study aimed to investigate whether lymph node status (LNS) could be included as one of the GPA variables for NSCLC with BMs.

Methods: Overall, 586 patients with NSCLC and BMs were retrospectively analyzed. Overall survival stratified by LNS was analyzed using the Kaplan-Meier method. Multivariate analysis was also performed to identify independent prognostic factors using the Cox proportional hazards progression model. In the updated GPA index, prognostic factors and criteria of GPA score were weighted by effect magnitude relative risk (RR) and statistical significance.

Results: In NSCLC patients with BMs, those with lymph node involvement had worse overall survival (mOS, 13.4 months vs. 25.9 months, P <0.001) than those without lymph node involvement. Multivariate analysis showed that LNS might be an independent prognostic factor (RR: 1.702, CI: 1.340-2.162, P <0.001). Finally, five prognostic factors including LNS, the age of the patient, Karnofsky performance status (KPS), the number of BMs, and extracranial metastases were enrolled in our novel GPA index. With the updated GPA index involving the N stage, survival analysis was also performed. Prognostic results were significantly different among these four subgroups (Class A vs. Class B, P=0.047; Class B vs. Class C, P<0.001; Class C vs. Class D, P=0.007).

Conclusions: These results indicate that LNS might be an indispensable prognostic factor in NSCLC with BM. The novel GPA model involving the N stage could provide more reliable evidence to estimate the survival of NSCLC patients with BMs.

Citing Articles

Molecular and metabolic orchestration of the lymphatic vasculature in physiology and pathology.

Montenegro-Navarro N, Garcia-Baez C, Garcia-Caballero M Nat Commun. 2023; 14(1):8389.

PMID: 38104163 PMC: 10725466. DOI: 10.1038/s41467-023-44133-x.

Heterogeneity in intracranial relapses after complete resection of lung adenocarcinoma: Distinct features of brain-only relapse versus synchronous extracranial relapse.

Xu F, Li J, Xing P, Liu Y, Wang Y Cancer Med. 2023; 12(11):12495-12503.

PMID: 37062064 PMC: 10278484. DOI: 10.1002/cam4.5961.

Prognostic value of thoracic tumor staging and volume parameters in non-small cell lung cancer patients with synchronous solitary bone metastasis.

Deng K, Li S, Zhang J, Ye X, Yao K, Li Y J Thorac Dis. 2022; 14(4):1130-1138.

PMID: 35572912 PMC: 9096287. DOI: 10.21037/jtd-22-113.

Integrative lymph node-mimicking models created with biomaterials and computational tools to study the immune system.

Shou Y, Johnson S, Quek Y, Li X, Tay A Mater Today Bio. 2022; 14:100269.

PMID: 35514433 PMC: 9062348. DOI: 10.1016/j.mtbio.2022.100269.

Construction and validation of a nomogram for non small cell lung cancer patients with liver metastases based on a population analysis.

Zhao R, Dai Y, Li X, Zhu C Sci Rep. 2022; 12(1):4011.

PMID: 35256719 PMC: 8901853. DOI: 10.1038/s41598-022-07978-8.

References

Wu Y, Zhou C, Cheng Y, Lu S, Chen G, Huang C . Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol. 2012; 24(4):993-9. DOI: 10.1093/annonc/mds529. View

Gould M, Kuschner W, Rydzak C, Maclean C, Demas A, Shigemitsu H . Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003; 139(11):879-92. DOI: 10.7326/0003-4819-139-11-200311180-00013. View

Rice S, Molitoris J, Vyfhuis M, Edelman M, Burrows W, Feliciano J . Lymph Node Size Predicts for Asymptomatic Brain Metastases in Patients With Non-small-cell Lung Cancer at Diagnosis. Clin Lung Cancer. 2018; 20(1):e107-e114. DOI: 10.1016/j.cllc.2018.09.014. View

Reungwetwattana T, Nakagawa K, Cho B, Cobo M, Cho E, Bertolini A . CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018; :JCO2018783118. DOI: 10.1200/JCO.2018.78.3118. View

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

Sperduto P, Kased N, Roberge D, Xu Z, Shanley R, Luo X . Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2011; 30(4):419-25. PMC: 3269967. DOI: 10.1200/JCO.2011.38.0527. View

Mountain C . Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111(6):1710-7. DOI: 10.1378/chest.111.6.1710. View

Yamamoto M, Serizawa T, Shuto T, Akabane A, Higuchi Y, Kawagishi J . Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014; 15(4):387-95. DOI: 10.1016/S1470-2045(14)70061-0. View

Cai L, Zhu J, Zhang X, Lin S, Su X, Lin P . A comparative analysis of EGFR mutation status in association with the efficacy of TKI in combination with WBRT/SRS/surgery plus chemotherapy in brain metastasis from non-small cell lung cancer. J Neurooncol. 2014; 120(2):423-30. PMC: 4206296. DOI: 10.1007/s11060-014-1570-7. View

10.

Li W, Zhao T, Xu H, Wang Z, Xu Y, Han Y . The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer. 2019; 19(1):145. PMC: 6375157. DOI: 10.1186/s12885-019-5331-z. View

11.

Bauer T, Shaw A, Johnson M, Navarro A, Gainor J, Thurm H . Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. Target Oncol. 2020; 15(1):55-65. PMC: 7028836. DOI: 10.1007/s11523-020-00702-4. View

12.

Detterbeck F, Boffa D, Tanoue L . The new lung cancer staging system. Chest. 2009; 136(1):260-271. DOI: 10.1378/chest.08-0978. View

13.

Stuschke M, Eberhardt W, Pottgen C, Stamatis G, Wilke H, Stuben G . Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol. 1999; 17(9):2700-9. DOI: 10.1200/JCO.1999.17.9.2700. View

14.

Sperduto P, Yang T, Beal K, Pan H, Brown P, Bangdiwala A . Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2016; 3(6):827-831. PMC: 5824323. DOI: 10.1001/jamaoncol.2016.3834. View

15.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

16.

Sperduto P, Berkey B, Gaspar L, Mehta M, Curran W . A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2007; 70(2):510-4. DOI: 10.1016/j.ijrobp.2007.06.074. View

17.

Iida T, Shiba M, Yoshino I, Miyaoka E, Asamura H, Date H . Surgical Intervention for Non-Small-Cell Lung Cancer Patients with Pleural Carcinomatosis: Results From the Japanese Lung Cancer Registry in 2004. J Thorac Oncol. 2015; 10(7):1076-82. DOI: 10.1097/JTO.0000000000000554. View

18.

Gray P, Mak R, Yeap B, Cryer S, Pinnell N, Christianson L . Aggressive therapy for patients with non-small cell lung carcinoma and synchronous brain-only oligometastatic disease is associated with long-term survival. Lung Cancer. 2014; 85(2):239-44. PMC: 4592138. DOI: 10.1016/j.lungcan.2014.06.001. View

19.

Dai C, Ren Y, Xie D, Zheng H, She Y, Fei K . Does Lymph Node Metastasis Have a Negative Prognostic Impact in Patients with NSCLC and M1a Disease?. J Thorac Oncol. 2016; 11(10):1745-54. DOI: 10.1016/j.jtho.2016.06.030. View

20.

Balasubramanian S, Sharma M, Venur V, Schmitt P, Kotecha R, Chao S . Impact of EGFR mutation and ALK rearrangement on the outcomes of non-small cell lung cancer patients with brain metastasis. Neuro Oncol. 2019; 22(2):267-277. PMC: 7442419. DOI: 10.1093/neuonc/noz155. View